Department of Radiation Oncology, Apollo Multispeciality Hospitals, Kolkata, India.
Manipal Hospitals, Dwarka, New Delhi, India.
Sci Rep. 2023 Mar 1;13(1):3430. doi: 10.1038/s41598-023-30429-x.
This study evaluates the volumetric modulated arc therapy (VMAT) dosimetric comparison between Halcyon ring gantry and TrueBeam c-arm linear accelerators for craniospinal irradiation (CSI) of the neuro-axis. 25 patients, who received treatment for medulloblastoma and primitive neuro-ectodermal tumors between 2018 and 2021, were planned for VMAT in True Beam (TB), and Halcyon (HAL) linear accelerators using 6 MV unflattened (FFF) photon beams (HALFFF and TBFFF). Dose-volume statistics for the target and organs at risk (OARs) and the total number of monitoring units (MUs) in the treatment plans were compared which included dose received by 95% PTV volume (V95%), volume receiving ≥ 107% dose, homogeneity index (HI), conformity index (PI), MU and dose spillage (D10%, D30%, D50%, D70%, D90%). In all 26 OARs were considered of which five were serial and the remaining were parallel structures. For the former, the dose received by 0.2 cm, volume = D0.2 cm) were evaluated and for the latter mean dose were evaluated. Both arms were statistically compared with paired sample t-test with a significant value of ≤ 0.05. 11 patients received treatment with the Halcyon and the rest 14 in the TrueBeam C-arm linear accelerator. Patients in the low- and intermediate-risk category (n = 13) received 23.4 Gy in 13 fractions. The remaining patients were in the high-risk category and received 35 Gy in 21 fractions or 36 Gy in 20 fractions. For HALFFF and TBFFF, PTVV95% were 97.5 ± 0.8% and 97.4 ± 0.9% respectively (p = 0.371) while the V107% were 0.6 ± 0.4% and 0.5 ± 0.5 respectively (p = 0.504). However, the number of monitoring units showed statistical significance (p < 0.001) with values of 1331.9 ± 243.4 MU and 1089 ± 206.7 MU respectively for the HAL and TB plans. The differences in spillage dose were also statistically significant, favouring HAL plans at D30% (p = 0.002), D50% (p < 0.001), D70% (p = 0.039), and D90% (p = 0.01) level except for D10% (p = 0.090). Conformity index also showed statistical significance with PI_HAL = 0.9 ± 0.02 and PI_TB = 0.89 ± 0.03 (p = 0.029). For 10 of the 21 parallel structures, the mean dose differences were statistically significant in favouring of HAL plans. Halcyon based VMAT CSI plans are dosimetrically superior in terms of organ dose, especially for the large organs, and offer lower spillage doses than the TrueBeam plans. Plans generated by both linear accelerators are suitable for the patients' treatments.
这项研究评估了 Halcyon 环形机架和 TrueBeam c 臂直线加速器在颅脊柱照射(CSI)神经轴中的容积调制弧形治疗(VMAT)剂量学比较。2018 年至 2021 年间,25 名接受髓母细胞瘤和原始神经外胚层肿瘤治疗的患者在 TrueBeam(TB)和 Halcyon(HAL)直线加速器中使用 6 MV 平坦化(FFF)光子束(HALFFF 和 TBFFF)进行 VMAT 计划。比较了靶区和危及器官(OAR)的剂量体积统计数据以及治疗计划中的总监测单位(MU)数,其中包括 95% PTV 体积(V95%)、体积接受≥107%剂量、均匀性指数(HI)、适形性指数(PI)、MU 和剂量泄漏(D10%、D30%、D50%、D70%、D90%)。共考虑了 26 个 OAR,其中 5 个为串联结构,其余为并行结构。对于前者,评估了 0.2cm 处的剂量(D0.2cm)和体积,对于后者,评估了平均剂量。两个臂都用配对样本 t 检验进行了统计学比较,显著性值为≤0.05。11 名患者在 Halcyon 接受治疗,其余 14 名患者在 TrueBeam C 臂直线加速器接受治疗。低危和中危组(n=13)患者接受 23.4Gy/13 次分割。其余患者为高危组,接受 35Gy/21 次分割或 36Gy/20 次分割。对于 HALFFF 和 TBFFF,PTVV95%分别为 97.5±0.8%和 97.4±0.9%(p=0.371),而 V107%分别为 0.6±0.4%和 0.5±0.5%(p=0.504)。然而,监测单位数量显示出统计学意义(p<0.001),HAL 和 TB 计划的 MU 值分别为 1331.9±243.4 MU 和 1089±206.7 MU。泄漏剂量的差异也具有统计学意义,HAL 计划在 D30%(p=0.002)、D50%(p<0.001)、D70%(p=0.039)和 D90%(p=0.01)水平上具有优势,D10%除外(p=0.090)。适形性指数也具有统计学意义,PI_HAL=0.9±0.02,PI_TB=0.89±0.03(p=0.029)。对于 21 个并行结构中的 10 个,HAL 计划的平均剂量差异具有统计学意义。基于 Halcyon 的 VMAT CSI 计划在器官剂量方面具有优势,特别是对于大器官,并且比 TrueBeam 计划提供更低的泄漏剂量。这两种线性加速器生成的计划都适合患者的治疗。